Form 4: CVS Health Executive Reports Stock Transactions

CVS Health Corp. executive Samrat S. Khichi reported transactions involving restricted stock units and common stock, including the surrender of shares for tax payments.

Summary

• Samrat S. Khichi, EVP, CPO and General Counsel at CVS Health Corp., reported a transaction on March 31, 2026, involving the acquisition of 12,531 restricted stock units at a price of $71.82 per share, bringing his total beneficial ownership of common stock to 38,139.
• On April 1, 2026, Khichi disposed of 3,541 shares of common stock for $72.49 per share, reducing his direct beneficial ownership to 33,421 shares.
• Additionally, Khichi acquired a stock option on March 31, 2026, with an exercise price of $71.82, representing 80,838 shares of common stock. This option becomes exercisable in three equal annual installments starting March 31, 2027, and expires on March 31, 2036.
• The restricted stock units awarded to Khichi have restrictions that lapse in three equal installments, beginning on March 31, 2027.
• The disposal of 3,541 shares on April 1, 2026, was a surrender of shares to pay withholding taxes due upon the vesting and settlement of restricted stock units.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it primarily details routine executive stock transactions and tax payments rather than significant strategic shifts or performance indicators.

Positives

• Acquisition of 12,531 restricted stock units, indicating continued equity-based compensation and potential future value.
• Acquisition of a stock option for 80,838 shares, providing potential upside if the stock price increases.
• The stock option and restricted stock units vest over time, aligning executive incentives with long-term company performance.

Negatives

• Surrender of 3,541 shares to cover tax obligations, reducing the executive's direct shareholding.
• The exercise price of the stock option ($71.82) is close to the current market price, suggesting limited immediate intrinsic value for the option.

Risks

• The vesting of restricted stock units and exercisability of stock options are contingent on continued employment and future company performance.
• Tax withholding obligations may require the sale of shares or stock options in the future.

Future Outlook

The filing indicates that restricted stock units will vest and stock options will become exercisable in installments starting March 31, 2027, suggesting a phased approach to executive equity realization over several years.

Industry Context

StockSavvy.ai notes that this Form 4 filing is typical for executives in the healthcare and retail pharmacy sector, reflecting standard practices for equity-based compensation and tax management. The transactions align with industry norms for incentivizing senior leadership.

Stakeholder Impact

• Shareholders: The transactions do not immediately indicate a change in beneficial ownership that would significantly impact control, but reflect ongoing executive compensation practices.
• Employees: The filing is specific to an executive and does not directly impact general employee compensation or benefits.
• Creditors: No direct impact on creditors is indicated by these stock transactions.

Next Steps

• Vesting of restricted stock units in three equal installments, commencing March 31, 2027.
• Exercisability of stock options in three equal annual installments, commencing March 31, 2027.

Key Dates

Keywords

CVS Health, Form 4, Insider Trading, Stock Options, Restricted Stock Units, Executive Compensation, Beneficial Ownership, SEC Filing, Samrat S. Khichi